untitled

Transcription

1 異 欄 Gliadel Wafer 7.7 mg/pce 異 carmustine 8 零 20 度 不 療 2008/12/17 Clexane 6000 anti-xa 60 mg/0.6 ml /amp Pregnyl 1500 IU/amp enoxaparin sodium human chorionic gonadotropin 復 復 流 Fluarix, adult 0.5 ml/syrg 流 Vaxigrip, ped 0.25 ml/syrg 12 1 量 療 流 Vaxigrip, adult 0.5 ml/syrg 2008/11/ /12/ /12/3 異 欄 年 12 2 異 4 Polifeprosan 20 with carmustine implant Gliadel Wafer 立 5 Tetrabenazine Nitoman ()... 6 Decitabine Dacogen ()... 7

2 <> Glyceryl trinitrate Concentrate Inj 50 mg/10 ml /amp nitroglycerin 領 益 留 療 2008/12/ 年 Innohep (tinzaparin sodium injection) FDA 臨 Innohep in Renal Insufficiency Study (IRIS) 2008 年 料 Innohep 率都 參 2008 年 7 Innohep Innohep 不 90 老 FDA IRIS 臨 數 不 90 老 率 FDA Innohep heparin() 臨 Innohep 不 老年 70 率 不 / 料 FDA 2009 年 1 IRIS 臨 FDA 行 論 FDA 數 Innohep Celgene 臨 不 老 Innohep heparin 更易 療 不 老 不論 塞都 Innohep 參 FDA htm#innohep 2008/12/2 & 2008/12/ meq Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection, USP Hospira, Inc. 20 meq Potassium Chloride in 5% Dextrose and 0.45% Sodium Chloride Injection ( FW2010/5/NDC ml ) 數 5% Dextrose InjectioUSP (NDC ) 不 療 不良 不 不 異 精神 亂 2008 年 年 9 療 若 立 Hospira 聯 聯 參 FDA /12/09

3 3. Healon D Ophthalmic Viscosurgical Device Advanced Medical Optics (AMO) FDA Healon D Ophthalmic Viscosurgical Device (OVD) UD mg/ml 量 量 AMO 連 聯 參 FDA htm#healon 2008/12/11 4. Oral Sodium Phosphate (OSP) Products for Bowel Cleansing (marketed as Visicol and OsmoPrep, and oral sodium phosphate products available without a prescription) FDA 類 sodium phosphate products (OSP) () 類 VisicolOsmoPrep OSPs (Fleet Phospho-soda) 例 FDA Visicol OsmoPrep OSPs FDA 行 略 臨 FDA 不 OSP OSPs 參 FDA htm#osp 2008/12/12 Fleet Ready to Use Enema 133 ml/btl (monobasic sodium phosphate, dibasic sodium phosphate ) 利 樂利 ( 不 ) Fleet Phospho-Soda Oral Saline Laxative 45 ml/btl (each 5 ml contains monobasic sodium phosphate 2.4 g, dibasic sodium phosphate 0.9 g) 利 5. Weight Loss Pills FDA 25 sibutramine ( ) rimonabant () phenytoin ()phenolphthalein ( ) 不 路 零 行 不良 ( )FDA 立 FDA 勵 25 見 FDA 參 FDA htm#weight 2008/12/22 6. Hydromorphone HCl 2 mg Tablets ETHEX FDA hydromorphone HCl 2 mg Hydromorphone 療 量 ( 藍 "E""2" ETHEX KV Pharmaceutical FDA KV 理 理

4 列 見 列 參 FDA htm#hydromorphone 2008/12/24 異 () 97 年 Antineoplastics drugs 98 年 dasatinib ( Sprycel)(98/1 /1) 1. 療 imatinib 400 mg() 療 2. 療 淋 imatinib 400 mg() 療 3. 歷 imatinib 不良. () 97 年 Exelon capsules) (90/10/1)galantamine hydrobromide ( Reminyl) (92/1/ 95/6/1) 度 度 MMSE 10~26 CDR 1 2 類 不 歷 理 Antineoplastics drugs 98 年 Oxaliplatin89/7/191/10/1 93/8/1 98/2/ FU folinic acid (1) 療 若 irinotecan Campto 不 (91/10/1) (2) (Duke's C) 切 療 98/2/1 2. Capecitabine 復 / 療 Eloxatin Oxalip 98/2/1 () 97 年 神 Drugs acting on the nervous system 98 年 療 donepezil ( Aricept)rivastigmine ( Exelon capsules) (90/10/1)galantamine hydrobromide ( Reminyl) (92/1/1)memantine ( Witgen Ebixa ) (95/6/1) 1. 列 神 精神 NINDS-ADRDA DSM ICD MMSE CDR (1) donepezil ( Aricept)rivastigmine( (93/4/1) 神 精神 六 MMSE CDR MMSE 療 2 ( 不 ) CDR 1 類 (98/1/1) (2) memantine WitgenEbixa(95/6/1 度 度 (10MMSE14

5 CDR 2 ) donepezil, rivastigmine, galantamine 若不 MMSE CDR (10MMSE14 CDR 2 ) memantine memantine 不 神 精神 六 MMSE CDR MMSE 療 2 ( 不 ) CDR 1 類 (98/1/1) 2. 臨 heart block 不 3. 料 (93/4/ 95/6/1) (1) CTMRI 金 量 Hachinskki lschemic Scale (2) CB, VDRL, BUN, Creatinine, GOT, GPT, T4, TSH (3) 歷 (4) 95/6/1 (5) MMSE CDR Polifeprosan 20 with carmustine implant Gliadel Wafer 立 羅 狀 Gliadel Wafer1.451 polifeprosan 20 (polyanhydride copolymer) carmustine 7.7 Carmustinepolifeprosan 20 prolifeprosan 20carmustine 理 Gliadel Wafercarmustine DNARNA 惡 力 Gliadel Waferpolifeprosan 20 70% carboxyphenoxypropane sebacic acid Prolifeprosan 20 不 Gliadel Wafer carmustine 度 量 Gliadel Wafer 率 異 見 留 復 神 不良 1. 度惡 神 復 臨 兩 率 19% 率 54% (12/22Gliadel Wafer)9% (2/22 ) 數 Gliadel Wafer 罹 度惡 神 療臨 率 22.5% (Gliadel Wafer)19.2%( )( 復 ) Gliadel Wafer 留 3. 異 度惡 神 復

6 臨 異 率 14%(Gliadel Wafer)5%() 4. 度惡 神 復 臨 率 4%(Gliadel Wafer ) 1%( ) Gliadel Wafer 塞 Gliadel Wafer Gliadel Wafer D carmustine Gliadel Wafer Gliadel Wafer 療 Gliadel Wafer 療 Gliadel Wafer 見 量 Gliadel Wafercarmustine 7.7 mg 量 61.6 mg 量 Gliadel Wafer 若 不 數 Gliadel Wafer 臨 不 Gliadel Wafer 立 Gliadel wafer carmustine 兩 若 Gliadel Wafer Gliadel Wafer Gliadel Wafer 都 狀 不 切 理 留 Gliadel Wafer 裂 裂 兩 (Surgicel ) Gliadel Wafer 6 零 20C 參 料 1. McEvoy GK, ed. AHFS: Drug Information. Bethesda, MD: American Society of Health-System Pharmacists; 2008: DRUGDEX System:Klasco RK (Ed): DRUGDEX System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: (cited: 5/18/2008). 3. The circular from the manufacturer of Gliadel Wafer. 4. Brem H, Piantadosi S, Burger PC, et al. Placebocontrolled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 1995; 345: Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro-Oncol 2003; 5: Westphal M, Ram Z, Riddle V, et al. Gliadel wafer in initial surgery for malignant gliomas: long-term followup of a multicenter controlled trial. Acta Neurochir 2006; 148: Tetrabenazine Nitoman () 林

7 狀 Nitoman CL25 tetrabenazine 25 mg 理 Tetrabenazinebenzoquinolizine 來 療 Tetrabenazine 神 (vesicular) 類神 dopamine norepinephrine serotonin 度 acetylcholin glutamatasparate 度 類 reserpine 力 Tetrabenazine 率 不穏 hydroxytetrabenazine (Huntington's disease) 不良 不 (27.4%)(<5%) 不 1. Tetrabenazine 車 2. tetrabenazine 3. 糖 lactose 見 糖不 galactose intolerancelapp 糖 Lapp lactase deficiency 糖 - 糖 不良 glucose-galactose malabsorption 不 料 MAOI MAOI 若 2 Tetrabenazine parkinsonian symptomslevodopa 量 量 mg mg 量 200 mg( 量 ) <30 參 料 1. DRUGDEX System:Klasco RK (Ed): DRUGDEX System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: (cited:4/3/2008). 2. The information from the manufacturer of Nitoman. Decitabine Dacogen () 羅 狀 狀 decitabine 100 mg. 理 Decitabine DNADNA methyltransferase DNAdecitabine ( ) 復 decitabine 來 DNA methyltransferase DNA decitabine

8 力 臨 decitabine mg/m 2 /day72 廓 率 124 L/hr/m ±0.31 率 <1% Decitabine 類 切 cytidine deaminase 粒 FDA 療 療 不 (myelodysplastic syndromes) FAB(French-American- British) IPSS (International Prognostic Scoring System) 數 >0.5 不良 ( ) 療 量 見 MDS 臨 decitabine 率 90% 89% 82%grade 34 率 87%85% 見不良 異 ( 數 ) 見 兩 臨 度 CYP450 量 FDA 量 15 mg/m 2 38 連 3 理 立 臨 參 療 Dacogen10 ml(2-8)ml decitabine 5 mg 立 0.9% sodium chloride Injection5% dextrose injection lactated ringer s injection 度 mg/ml15 (2-8)2-8 7 (15-30 參 料 1. Decitabine. From AHFS Drug Information (electronic version). At: STAT!Ref Online Electronic Medical Library. Bethesda, MD: American Society of Health-System Pharmacists, Inc.; Accessed: 10/31/2008). 2. Klasco RK (Ed): DRUGDEX System (electronic version). Thomson Micromedex, Greenwood Village, Colorado, USA. Available at: (cited: 10/31/2008). 3. The circular from the manufacturer of Dacogen. FDAD decitabine 料 率 (<1%)